Pemeriksaan Kadar Asam Urat sebagai Upaya Deteksi Dini Hiperurisemia dan Edukasi Pencegahan Komplikasi pada Masyarakat
Keywords:
Hiperurisemia, Deteksi Dini, Edukasi Kesehatan.Abstract
Hiperurisemia merupakan kondisi peningkatan kadar asam urat dalam darah yang berpotensi berkembang menjadi gout arthritis serta berhubungan dengan berbagai penyakit metabolik dan kardiovaskular. Pemeriksaan kadar asam urat secara rutin belum menjadi kebiasaan di masyarakat, sehingga deteksi dini dan edukasi kesehatan perlu ditingkatkan. Kegiatan pengabdian kepada masyarakat ini bertujuan untuk melakukan skrining kadar asam urat serta memberikan edukasi mengenai faktor risiko dan pencegahan hiperurisemia. Metode yang digunakan adalah pendekatan deskriptif melalui pemeriksaan darah kapiler menggunakan alat Point of Care Testing (POCT), dengan analisis distribusi berdasarkan jenis kelamin, kelompok usia, dan kategori kadar asam urat. Sebanyak 38 peserta mengikuti kegiatan ini, dengan 31,58% teridentifikasi mengalami hiperurisemia dan 68,42% berada dalam kategori normal. Proporsi hiperurisemia sedikit lebih tinggi pada laki-laki (33,33%) dibandingkan perempuan (31,03%), serta meningkat signifikan pada kelompok usia ≥50 tahun (50,00%). Temuan ini menunjukkan kecenderungan peningkatan risiko hiperurisemia pada usia lanjut dan menegaskan pentingnya skrining serta edukasi pola hidup sehat sebagai strategi promotif dan preventif dalam mendukung kesehatan masyarakat.
Downloads
References
Choi, H. K., & Curhan, G. (2008). Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ : British Medical Journal, 336(7639), 309. https://doi.org/10.1136/bmj.39449.819271.BE
Dalbeth, N., Merriman, T. R., & Stamp, L. K. (2016). Gout. The Lancet, 388(10055), 2039–2052. https://doi.org/10.1016/S0140-6736(16)00346-9
Dehlin, M., Jacobsson, L., & Roddy, E. (2020). Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews. Rheumatology, 16(7), 380–390. https://doi.org/10.1038/s41584-020-0441-1
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008). Uric Acid and Cardiovascular Risk. The New England Journal of Medicine, 359(17), 1811. https://doi.org/10.1056/nejmra0800885
Fulden Aydın, Ü., Kozanoğlu, E., & Tuli, A. (2024). High Fructose Consumption and Metabolic Syndrome from Gout Perspective. Cerrahpaşa Medical Journal, 48(2), 191–196. https://doi.org/10.5152/cjm.2024.24001
Grassi, D., Ferri, L., Desideri, G., Giosia, P. Di, Cheli, P., Pinto, R. Del, Properzi, G., & Ferri, C. (2013). Chronic Hyperuricemia, Uric Acid Deposit and Cardiovascular Risk. Current Pharmaceutical Design, 19(13), 2432–2438. https://doi.org/10.2174/1381612811319130011
Guo, K., Han, Y., Liu, S., Sun, H., Lin, X., Yang, S., Gao, Y., & Chen, H. (2024). Prevalence of and trends in hyperuricemia by race and ethnicity among US adolescents, 1999–2018. Arthritis Research & Therapy, 26(1), 193. https://doi.org/10.1186/s13075-024-03427-1
Johnson, R. J., Nakagawa, T., Sanchez-Lozada, L. G., Shafiu, M., Sundaram, S., Le, M., Ishimoto, T., Sautin, Y. Y., & Lanaspa, M. A. (2013). Sugar, Uric Acid, and the Etiology of Diabetes and Obesity. Diabetes, 62(10), 3307–3315. https://doi.org/10.2337/db12-1814
Krishnan, E. (2012). Reduced glomerular function and prevalence of gout: NHANES 2009-10. PloS One, 7(11). https://doi.org/10.1371/journal.pone.0050046
Kuo, C. F., Grainge, M. J., Zhang, W., & Doherty, M. (2015). Global epidemiology of gout: prevalence, incidence and risk factors. Nature Reviews. Rheumatology, 11(11), 649–662. https://doi.org/10.1038/nrrheum.2015.91
Li, L., Yang, C., Zhao, Y., Zeng, X., Liu, F., & Fu, P. (2014). Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrology, 15(1). https://doi.org/10.1186/1471-2369-15-122
Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, & Weil PA. (2018). Biochemistry & Medicine | Harper’s Illustrated Biochemistry, 31e | AccessMedicine | McGraw Hill Medical (31st ed). McGraw-Hill. https://accessmedicine.mhmedical.com/content.aspx?bookid=2386§ionid=187830144
Neogi, T. (2011). Clinical practice. Gout. The New England Journal of Medicine, 364(5), 443–452. https://doi.org/10.1056/NEJMcp1001124
Richette, P., & Bardin, T. (2010). Gout. The Lancet, 375(9711), 318–328. https://doi.org/10.1016/S0140-6736(09)60883-7
Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., Lioté, F., Mallen, C., Nuki, G., Perez-Ruiz, F., Pimentao, J., Punzi, L., Pywell, T., So, A., Tausche, A. K., … Bardin, T. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 76(1), 29–42. https://doi.org/10.1136/annrheumdis-2016-209707
Roughley, M. J., Belcher, J., Mallen, C. D., & Roddy, E. (2015). Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Research & Therapy 2015 17:1, 17(1), 90-. https://doi.org/10.1186/s13075-015-0610-9
Shahin, L., Patel, K. M., Heydari, M. K., & Kesselman, M. M. (2021). Hyperuricemia and Cardiovascular Risk. Cureus, 13(5). https://doi.org/10.7759/cureus.14855
Stamp, L. K., & Chapman, P. T. (2013). Gout and its comorbidities: implications for therapy. Rheumatology, 52(1), 34–44. https://doi.org/10.1093/rheumatology/kes211
WHO. (2019). Medication Safety in Polypharmacy. World Health Organization. http://apps.who.int/bookorders.
Zhang, Y., Chen, C., Choi, H., Chaisson, C., Hunter, D., Niu, J., & Neogi, T. (2012). Purine-rich foods intake and recurrent gout attacks. Annals of the Rheumatic Diseases, 71(9), 1448. https://doi.org/10.1136/annrheumdis-2011-201215
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Fauziah Hasdin, Sri Wahyuningsih, Nur Afni, ST. Aisyah Humaerah (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
